At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 305 enrolled
Drug / intervention
Esomeprazole +1 moredrug
Likely dose
Esomeprazole 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Open-label Phase IV Study Exploring Symptom Control Rate in Co-diagnosed NERD and Chronic Gastritis Patients Treated With 8 Weeks Esomeprazole Treatment Regimen and 2 Weeks Esomeprazole Treatment Regimen
In Brief
A Phase 4 clinical trial evaluating Esomeprazole for Non Erosive Reflux Disease and Chronic Gastritis. Completed, enrolled 305 participants across 8 sites.
Detailed Summary
To compare the symptom control rate between 8 weeks esomeprazole treatment regimen group and 2 weeks esomeprazole treatment regimen group in co-diagnosed NERD and chronic gastritis patients, as evaluated by GerdQ after 24 weeks maintenance treatment/follow up.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Erosive Reflux Disease, Chronic Gastritis
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2010
First PostedMay 2010
Primary CompletionJun 2011
TodayJul 2026
First PostedMay 10, 2010
Enrollment StartApr 1, 2010
Primary CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 16.1 years ago
Interventions
Esomeprazoledrug
20mg Esomeprazole once daily, 8 weeks and 24 weeks on-demand treatment
Esomeprazoledrug
20mg Esomeprazole once daily, 2 weeks and 24 weeks follow up